A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs APD 371 (Primary)
- Indications Abdominal pain
- Focus Adverse reactions
- Sponsors Arena Pharmaceuticals
- 07 Aug 2017 According to an Arena Pharmaceuticals media release, data readout from the study is expected around year-end 2017 to Q1 2018.
- 15 May 2017 Status changed from planning to recruiting.
- 14 Mar 2017 According to an Arena Pharmaceuticals media release, the company is currently incorporating feedback related to study design and conduct into the clinical protocol design and selecting sites.